Syngene Intl Peer Comparison

NSE: SYNGENE | BSE: 539268

₹403.40

₹-10.40 (-2.51%)

As on 28-Aug-2026IST

Market cap

₹16,284 Cr

Revenue (TTM)

₹3,600 Cr

P/E Ratio

73.7

P/B Ratio

3.4

Div. Yield

0.3 %

Edit

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	16,284	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	3,600	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	221.00	414.00	288.22	-371.81	387.35
Net Margin (%)	6.01	11.23	14.79	-3.93	26.01
RoE (%)	5.62	8.38	29.77	-3.85	25.18
Price to Earnings	73.68	78.49	103.71	--	69.57
Price-To-Book	3.44	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	3,738.70	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	3,815.70	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	2,826.60	2,747.00	1,354.69	7,976.59	774.80
EBITDA	912.10	626.00	399.26	892.49	232.07
Depreciation	452.80	227.00	45.26	831.24	26.62
EBIT	459.30	399.00	354.00	61.25	205.45
Interest	48.80	213.00	42.17	340.80	6.22
Other Income	77.00	137.00	8.70	242.43	16.93
Exceptional Items	-76.60	-85.00	--	-196.14	--
Profit before Tax	410.90	238.00	320.53	-176.06	216.16
Provision for Tax	94.20	39.00	73.80	149.88	55.75
Profit after Tax	316.70	199.00	246.74	-325.94	160.42

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	4,839.10	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	--	341.00	0.00	--	10.45
Non-Current Liabilities	562.60	1,235.00	189.02	4,529.41	26.93
Current Liabilities	1,552.30	1,622.00	835.87	4,874.74	202.25
Total Liabilities	7,054.70	8,578.00	2,326.71	17,723.32	1,549.26

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	4,811.20	5,441.00	631.90	10,258.66	757.63
Current Assets	2,142.80	2,606.00	1,681.81	7,308.11	791.64
Total Assets	7,054.70	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	9.40	2,125.00	259.37	5,495.48	8.18
Net Current Assets	590.50	984.00	845.94	2,433.37	589.39
Contingent Liabilities	536.50	768.26	19.09	95.72	15.38

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	915.20	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-860.40	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	-215.00	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	-160.20	95.00	78.39	787.59	155.52

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	9.48	6.79	29.22	1.24	20.14
ROE (%)	6.74	4.29	27.84	-4.04	16.19
ROA (%)	4.62	2.53	13.11	-1.98	12.13
EBIT Margin (%)	26.46	22.62	23.26	12.80	24.73
Net Margin (%)	8.30	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	20.49	10.98	7.71	4.80	18.58

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	2.64	11.99	36.57	-3.08	40.34
EBIT Growth (%)	-11.18	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	-36.17	449.12	83.64	-457.66	229.35
EPS Growth (%)	-36.24	553.20	71.44	-456.91	67.16
Book Value Growth (%)	2.11	13.47	144.31	0.33	94.96

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	49.65	89.54	51.69	0.00	62.97
Price / Book Value	3.31	3.87	10.14	2.24	15.26
Dividend Yield (%)	0.32	0.00	0.19	0.00	0.06
EV/EBITDA	15.06	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	15,723.10	19,071.62	12,753.19	18,108.89	19,988.69

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.00	0.09	0.05	0.09	0.01
Current Ratio	1.38	1.61	2.01	1.50	3.91
Quick Ratio	1.29	1.06	1.14	0.87	3.02
Interest Coverage	9.42	2.12	8.60	0.48	35.76

	Syngene Intl	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	13.61	17.43	29.00	24.33	28.85
Asset Turnover	0.55	0.49	2.01	0.64	0.76
Receivable days	50.33	58.75	40.13	78.20	90.06
Inventory Days	14.43	75.82	60.29	93.30	61.02
Payable days	17,487.50	186.21	232.47	226.14	96.06
Cash Conversion Cycle	-17,422.74	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.